Application notes
Connecting the gut and liver – coming soon
A human relevant dual-organ microphysiological system for preclinical profiling of oral bioavailability
Efforts to improve the in vitro to in vivo translation of drug efficacy and safety data has led to the emergence of more human relevant microphysiological systems (MPS). Multiple, fluidically linked MPS can be linked to form multi-organ systems that simulate human processes which can be utilized to improve ADME and bioavailability estimations. ADME and bioavailability are central in determining the safety and toxicology profiles of compounds and are therefore crucial preclinical drug development measurements.
Posters
Connecting the human intestine and liver
A primary jejunum and primary hepatocyte multi-organ MPS for more predictive studies of human drug ADME and oral bioavailability
Traditional immortalized intestinal cell lines and suspension hepatocytes have absent or low levels of metabolic enzyme expression, and thus fail to predict first pass human metabolism and oral bioavailability.
Efforts to improve the in vitro to in vivo translation of drug efficacy and safety data has led to the emergence of more human relevant microphysiological systems (MPS) that consist of multiple, fluidically linked organs1.
Articles
Harnessing Microphysiological Systems to Bring Humanized Processes to ADME and Bioavailability Studies
Dr. Abbas discusses the common drawbacks of using conventional methods for ADME studies that can misinform the candidate selection process and dosage figures. He talks about how emerging complementary technologies, such as organ-on-a-chip (OOC), offer human-relevant in vitro preclinical data, and how using OOC can support the determination of human bioavailability to support drug dosing regiments, reduce side effects, and potentially recover flawed therapeutic candidates.
Brochures & Flyers
Organ-on-a-chip Contract Research Services Brochure
Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints.
Posters
A primary jejunum and primary hepatocyte multi-organ MPS
Find out how our gut-liver MPS recapitulates the physiological condition enabling oral drug dosing in vitro. This gut-liver model offers a vast improvement in the methods used to study PK or prodrugs.
Articles
ADME Studies: Determining Promising Drug Compounds
Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.
This article is taken from PharmTech, November 2022.
Articles
How to Keep Breathing – The Future of Inhaled Medication Testing
Dr Emily Richardson discusses the current challenges faced to bring inhaled therapeutics to the market and the potential of Organ-on-a-Chip to increase positive outcome by improving ADME drug testing.
This article is taken from International Biopharmaceutical Industry, Summer 2022.
Videos and animations
PhysioMimix Multi-organ System Animation
An introduction to the CN Bio PhysioMimix Multi-organ System. This animation demonstrates how our microphysiological system works, how to create a Gut/Liver-on-a-chip model and an example of its use in determining drug Bioavailability in vitro.
Posters
Why two organs are better than one
Abbas, Kostrzewski & Hughes
This poster demonstrates how a gut-liver MPS can improve oral bioavailability predictions by mimicking human oral and IV regimens. Thus improving the in vitro to in vivo translation of drug efficacy and safety.
Articles
Predicting Drug Bioavailability with the Modern-Day Toolkit
Animal models continue to be used in bioavailability research but limitations are serious and difficult to overcome. Find out how OOC can help solve your PK/PD and bioavailability issues.
This article is taken from International Biopharmaceutical Industry Winter 2021, pages 14-17.
Application notes
Improved prediction of oral bioavailability using a gut-liver microphysiological system
Abbas, Kostrzewski & Hughes
Central to the development of new drugs is an understanding of their pharmacokinetic properties, in particular their bioavailability. Here, we demonstrate the potential of a true 2-organ gut-liver MPS to better predict human bioavailability and improve in vitro to in vivo correlation.
Webinars
From Dose to Circulation: Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System
Webinar Series 4 Episode 4
In this webinar, Dr. Yassen Abbas discusses how CNBio’s gut-liver MPS can be used for in vitro determination of oral bioavailability. This application has been validated with drugs with known human bioavailability and with a mathematical model developed to enable prediction of oral bioavailability in silico.